VMDVMDHealthcare · Medical Devices

VMD Stock Forecast: Viemed Healthcare, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$8.54
−0.81% on the day

The median 12-month analyst price target for Viemed Healthcare, Inc. is $12. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 99 of 100 as at 21 Nov 2026 — among the strongest tenth.

Market cap
$322.8M
Ticker Nerd rank
99/ 100
Median analyst target
$12
Analysts covering
2
Revenue$78.1M+23.9% y/y
Operating income$5.1M
Net income$2.9M
Free cash flow$7.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.9%
1M
−12.9%
YTD
+14.9%
1Y
+34.5%
From 52W high
−30.7%
From 52W low
+34.5%
$6
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Viemed Healthcare, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
99/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
94
Value
86
Momentum
85
Quality
85
Accruals
85
Volatility
84
Growth
76
Revisions
49

Issuance (94): The share count has been shrinking and the company is not leaning on new borrowing.

Revisions (49): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

VMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$6$8$10$12$14Jan 26Apr 26Jul 26Oct 26VMDHigh $14Median $12Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
1
Buy
1
Hold
0
Sell
$10
Low
$12
Median
$14
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 Nov 2026Freedom BrokerMaintainsHold$11 → $10
24 Aug 2026Barrington ResearchInitiatesOutperform—
6 Aug 2026Freedom BrokerDowngradeHold$11
3 Nov 2021RBC CapitalMaintainsOutperform$13 → $9.00
5 Mar 2021RBC CapitalInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for VMD.

Market Radar

This page is one stock. Monday covers all of them.

VMD appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

VMD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Viemed Healthcare, Inc. returned +34.5% against +6.9% for the S&P 500, dividends included.

VMD vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180200Jan 26Apr 26Jul 26Oct 26VMDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−5.9%
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
22.4×

Cheaper than 40% of US stocks

Price / sales
1.0×

Cheaper than 65% of US stocks

Price / book
2.2×

Cheaper than 41% of US stocks

EV / EBITDA
5.8×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
32.0%

Higher than 67% of US stocks

Gross margin
57.7%

Higher than 71% of US stocks

Operating margin
8.4%

Higher than 61% of US stocks

Net margin
5.0%

Higher than 57% of US stocks

Returns & dividend
Return on equity
11.2%

Higher than 65% of US stocks

Return on assets
7.9%

Higher than 87% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Viemed Healthcare, Inc. has a market value of $322.8M and an enterprise value of $324.4M.

  • Revenue in the twelve months to 30 June 2026: $301.6M. The latest quarter grew 23.9% year on year.

  • Net income over the same four quarters: $15.0M, a 5.0% net margin.

  • Diluted earnings per share, trailing twelve months: $0.36.

  • Free cash flow in the twelve months to 30 June 2026: $29.2M.

  • Viemed Healthcare, Inc. spent $20.5M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 38.1M.

  • Trailing P/E: 22.4×; forward P/E: 21.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Viemed Healthcare, Inc. employs 1,490 people — $202K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

VMD and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
VMDViemed Healthcare, Inc.$322.8M99
CVCapsoVision, Inc.$325.1M18
MASS908 Devices, Inc.$355.7M77
INFUInfuSystem Holdings, Inc.$285.8M100
CERSCerus Corp.$373.6M96
TMCITreace Medical Concepts, Inc.$274.6M55
NPCENeuroPace, Inc.$267.7M73

Take a look at VMD’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Viemed Healthcare, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about VMD

What is the VMD stock price forecast for 2026-2027?

The median 12-month analyst price target for Viemed Healthcare, Inc. is $12, with estimates ranging from $10 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VMD stock a buy right now?

Of the 2 analysts covering Viemed Healthcare, Inc., 1 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Viemed Healthcare, Inc. 99 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VMD?

As at 21 Nov 2026, Viemed Healthcare, Inc. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Issuance (94 of 100).

Will VMD stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts is $12, and Ticker Nerd's factor model ranks Viemed Healthcare, Inc. 99 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VMD stock forecast for 2030?

No analyst covering Viemed Healthcare, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $14 over the next 12 months.

How has VMD stock performed over the past year?

Viemed Healthcare, Inc. returned +34.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Viemed Healthcare, Inc. do?

Viemed Healthcare, Inc. is a healthcare company that provides home medical equipment and post-acute respiratory care services in the United States. The company focuses on in-home treatment for patients with respiratory conditions, offering equipment, therapy support, and clinical services designed to help manage complex breathing disorders outside traditional hospital settings.

Company

About Viemed Healthcare, Inc.

Viemed Healthcare, Inc. is a healthcare company that provides home medical equipment and post-acute respiratory care services in the United States. The company focuses on in-home treatment for patients with respiratory conditions, offering equipment, therapy support, and clinical services designed to help manage complex breathing disorders outside traditional hospital settings. Its current product and service portfolio includes non-invasive ventilation, oxygen equipment, sleep apnea testing and treatment, positive airway pressure therapy, respiratory disease management, and related supplies and support services. Viemed also provides complementary clinical and staffing services that support patient care in the home. The company serves patients nationwide and operates within the broader home healthcare and durable medical equipment markets, where it plays a specialized role in respiratory-focused in-home care.

CEO Mr. Casey Hoyt · 1,490 employees · United States · https://www.viemed.com